Cidofovir
- Generic Name
- Cidofovir
- Brand Names
- Vistide
- Drug Type
- Small Molecule
- Chemical Formula
- C8H14N3O6P
- CAS Number
- 113852-37-2
- Unique Ingredient Identifier
- 768M1V522C
- Background
Cidofovir is an injectable antiviral medication employed in the treatment of cytomegalovirus (CMV) retinitis in patients diagnosed with AIDS. It suppresses CMV replication through selective inhibition of viral DNA synthesis. It was manufactured by Gilead and initially approved by the FDA in 1996, but has since been discontinued.
- Indication
用于治疗免疫功能缺陷患者不能耐受更昔洛韦和膦甲酸钠治疗或治疗无效的巨细胞病毒感染。
- Associated Conditions
- Cytomegalovirus Retinitis, Herpes Simplex Virus, Monkeypox, Variola Major (Smallpox)
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
- Conditions
- Cytomegalovirus RetinitisHIV Infections
- Interventions
- Device: Ganciclovir implant and oral ganciclovir
- First Posted Date
- 1999-09-24
- Last Posted Date
- 2016-03-14
- Lead Sponsor
- Johns Hopkins Bloomberg School of Public Health
- Target Recruit Count
- 61
- Registration Number
- NCT00000143
- Locations
- 🇺🇸
Department of Ophthalmology, New York Hospital-Cornell Medical Center, New York, New York, United States
🇺🇸Department of Ophthalmology, Mount Sinai School of Medicine, New York, New York, United States
🇺🇸Cullen Eye Institute, Baylor College of Medicine, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.